Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarkers in Alzheimer's disease drug development.

Literature DB >> 21052077

Biomarkers in Alzheimer's disease drug development.

Abstract

Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.

Entities: Disease

Mesh：

Substances：
Biomarkers

Year: 2010 PMID： 21052077 DOI： 10.1038/nm.2221

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

43 in total

1. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits.

Authors: Xiying Chen; Vincent A Magnotta; Kevin Duff; Laura L Boles Ponto; Susan K Schultz
Journal: J Neuropsychiatry Clin Neurosci Date: 2006 Impact factor: 2.198

2. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Authors: Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie
Journal: Lancet Neurol Date: 2008-07-30 Impact factor: 44.182

3. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors: Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal: Lancet Neurol Date: 2010-02-26 Impact factor: 44.182

Review 4. Lewy body pathology in Alzheimer's disease.

Authors: P T Kotzbauer; J Q Trojanowsk; V M Lee
Journal: J Mol Neurosci Date: 2001-10 Impact factor: 3.444

5. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Authors: Erik Portelius; Bianca Van Broeck; Ulf Andreasson; Mikael K Gustavsson; Marc Mercken; Henrik Zetterberg; Herman Borghys; Kaj Blennow
Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472

6. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Authors: K Ranga Rama Krishnan; H Cecil Charles; P Murali Doraiswamy; Jacobo Mintzer; Richard Weisler; Xin Yu; Carlos Perdomo; John R Ieni; Sharon Rogers
Journal: Am J Psychiatry Date: 2003-11 Impact factor: 18.112

7. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422

Review 8. A beta oligomers - a decade of discovery.

Authors: Dominic M Walsh; Dennis J Selkoe
Journal: J Neurochem Date: 2007-02-05 Impact factor: 5.372

Review 9. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors: John Hardy; Dennis J Selkoe
Journal: Science Date: 2002-07-19 Impact factor: 47.728

10. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Authors: N C Fox; R S Black; S Gilman; M N Rossor; S G Griffith; L Jenkins; M Koller
Journal: Neurology Date: 2005-05-10 Impact factor: 9.910

51 in total

1. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors: Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal: Arch Neurol Date: 2012-07

2. Learning from genetic forms of neurodegeneration.

Authors: Alexis Brice
Journal: Nat Med Date: 2010-12 Impact factor: 53.440

3. Searching for biomarkers in neurodegeneration.

Authors: Simon Lovestone
Journal: Nat Med Date: 2010-12 Impact factor: 53.440

4. Neurodegeneration and the neurovascular unit.

Authors: Berislav V Zlokovic
Journal: Nat Med Date: 2010-12 Impact factor: 53.440

5. Neurodegeneration and the neuroimmune system.

Authors: Joseph El Khoury
Journal: Nat Med Date: 2010-12 Impact factor: 53.440

Review 6. Platelets and Alzheimer's disease: Potential of APP as a biomarker.

Authors: Geneviève Evin; Qiao-Xin Li
Journal: World J Psychiatry Date: 2012-12-22

7. Evidence for ordering of Alzheimer disease biomarkers.

Authors: Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman
Journal: Arch Neurol Date: 2011-08-08

Review 8. It's all about tau.

Authors: Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal: Prog Neurobiol Date: 2018-12-31 Impact factor: 11.685

Review 9. Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Authors: Gaurav Pandey; Vibin Ramakrishnan
Journal: Biophys Rev Date: 2020-09-15

Review 10. Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.

Authors: Alison E Mungenast; Sandra Siegert; Li-Huei Tsai
Journal: Mol Cell Neurosci Date: 2015-12-04 Impact factor: 4.314